Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05960786 · ClinicalTrials.gov registry record · NA
Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand
A NA study, sponsored by Otolith Labs.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
NCT05960786 is a NA study that has completed, run by Otolith Labs. The registered enrollment target is 109 participants.
The verdict
NCT05960786, a NA study, has completed, sponsored by Otolith Labs.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
Study Summary
The goal of this virtual clinical trial is to determine the effectiveness of two study devices in providing temporary relief to adults aged 18-70 who suffer from symptoms of chronic vestibular vertigo. The main question\[s\] it aims to answer are: * Within an episode, is there a significant difference between the randomized study devices at the individual timepoints during the vertigo episode? * Within an episode, is there evidence of quantitative treatment at each individual timepoint during the vertigo episode? Participants will be: * Enrolled up to 49 days; 14 days in Baseline Phase (no device) and 21 days in Treatment Phase (study device) for Study Arm 1 or 28 days in Treatment Phase (study device) for Study Arm 2 * Randomized and stratified into groups based on diagnosis to be assigned a study device * Asked to use the study device as instructed by the study coordinator * Asked to download a study app to submit daily diaries regarding their symptoms and use of device, and to participate in tele-health visits with study coordinators * Asked to provide their vertigo diagnosis from their physician * Compensated for their participation Researchers will compare the randomized groups to see which groups respond better to which device.
Interventions
- DEVICE Otoband Experimental
- DEVICE Otoband Sham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2023-12-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05960786
The ClinicalTrials.gov registry entry for NCT05960786 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Otolith Labs, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Otoband Experimental is the first listed.
NCT05960786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05960786 about?
NCT05960786 is a clinical study titled "Treating the Symptoms of Vertigo in a Real-world Setting Using the OtoBand". The goal of this virtual clinical trial is to determine the effectiveness of two study devices in providing temporary relief to adults aged 18-70 who suffer from symptoms of chronic vestibular vertigo. The main question\[s\] it aims to answer are: * Within an episode, is there a significant differ...
What is the current status of trial NCT05960786?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2023-02-02. Estimated completion is 2023-12-07.
What interventions are being tested in trial NCT05960786?
The interventions under investigation include: Otoband Experimental (DEVICE), Otoband Sham (DEVICE).
Who is sponsoring clinical trial NCT05960786?
This trial is sponsored by Otolith Labs, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.